Lingyi Biotech Featured in Business Insider, ACESSNewswire & Other Major Financial Outlets

Lingyi Biotech is proud to share that it was recently featured in an article published by ACESSNewswire, highlighting the company’s progress in advancing next-generation gene therapies. The article explores Lingyi’s proprietary platforms, including LY-Capsid™, LY-Promoter™, and LY-Vector™, which are designed to improve targeting, safety, and efficacy across a range of genetic diseases.

Following its release, the article was syndicated across several major financial news platforms, including:
• Yahoo Finance
• Business Insider
• Financial Content

This media coverage marks an exciting milestone as Lingyi Biotech continues to bring cutting-edge therapies closer to patients worldwide.